PingChiMDPhD

Hematologic Oncology, Melanoma, Sarcoma

Member and Attending Physician, Memorial Sloan-Kettering Cancer Center.

Overview of Dr. Chi

Dr. Ping Chi is an oncologist in New York, NY and is affiliated with Memorial Sloan Kettering Cancer Center. She received her medical degree from Weill Cornell Medicine and has been in practice 14 years. Dr. Chi accepts several types of health insurance, listed below. She is one of 497 doctors at Memorial Sloan Kettering Cancer Center who specialize in Oncology. She has more than 90 publications and over 500 citings.

Office
160 East 53rd Street
New York, NY 10022
Book by Phone+1(701) 369-9058

Education & Training

Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2005 - 2010
Brigham and Women's HospitalResidency, Internal Medicine, 2003 - 2005
Weill Cornell MedicineClass of 2003

Certifications & Licensure

FL State Medical License 2021 - Present
NY State Medical License 2004 - 2026
NJ State Medical License 2019 - 2025
NC State Medical License 2020 - 2022
American Board of Internal Medicine Medical Oncology

Clinical Trials

MEK162 in Combination With Imatinib Mesylate in Patients With Untreated Advanced Gastrointestinal Stromal Tumor (GIST) Start of enrollment: 2013 Nov 01
Active, not recruiting
Phase 1, Phase 2
Multi-Institutional Registry for Malignant Peripheral Nerve Sheath Tumors Start of enrollment: 2017 Apr 28
Recruiting
A Study of MEK162 (Binimetinib) in Combination With Pexidartinib in Patients With Advanced Gastrointestinal Stromal Tumor (GIST) Start of enrollment: 2017 Apr 15
Completed
Phase 1
A Study of Ripretinib vs Sunitinib in Advanced GIST Patients After Treatment With Imatinib Start of enrollment: 2019 Feb 08
Active, not recruiting
Phase 3
Join now to see all

Publications & Presentations

PubMed

Histology-Specific Clinical Trial of Lenvatinib and Pembrolizumab in Patients with Sarcoma.
Sujana Movva, Kenneth Seier, Viswatej Avutu, Lauren B Banks, Jason Chan
Clinical Cancer Research. 2024-12-16
MEK Inhibitors Lead to PDGFR Pathway Upregulation and Sensitize Tumors to RAF Dimer Inhibitors in NF1-Deficient Malignant Peripheral Nerve Sheath Tumor.
Miguel A Miranda-Román, Cindy J Lee, Eve Fishinevich, Leili Ran, Amish J Patel
Clinical Cancer Research. 2024-11-15
2 citations
Interpretable artificial intelligence to optimise use of imatinib after resection in patients with localised gastrointestinal stromal tumours: an observational cohort ...
Dimitris Bertsimas, Georgios Antonios Margonis, Suleeporn Sujichantararat, Angelos Koulouras, Yu Ma
The Lancet. Oncology. 2024-08-01

Press Mentions

Researchers Look for New Ways to Attack Resistant CancersNovember 14th, 2024

Insurance Accepted

Aetna Choice POS II
Aetna HMO
Anthem Blue Access PPO
Anthem Blue Preferred HMO
Anthem Blue Preferred Plus POS
BCBS Blue Card PPO
BCBS Illinois PPO
BCBS Texas BlueChoice
CIGNA HMO
CIGNA Open Access
CIGNA PPO
Empire BCBS HMO
Empire BCBS PPO
First Health PPO
Great West PPO
Humana ChoiceCare Network PPO
Multiplan PHCS PPO
Multiplan PPO
MVP Healthcare PPO
Oxford Health Freedom
Oxford Health Liberty
United Healthcare - Direct Choice Plus POS
United Healthcare - Direct Options PPO
WEA Trust POS-SE
WEA Trust Preferred Provider Plan - Trust Pref
Please verify your coverage with the provider's office directly when scheduling an appointment